Sanofi Pasteur’s Dengue vaccine Candidate Successfully Completes Final Landmark Phase III Clinical Efficacy Study in Latin America

Second, large-scale phase III study successfully meets primary endpoint with overall vaccine efficacy of 60.8 percent and shows efficacy against each of the four dengue serotypes – Additional observation of the results shows a significant reduction of the risk of hospitalization by 80.3 percent confirming the potential public health impact of the vaccine Initial safety data are consistent with the …